Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Abbott Laboratories ( ABT) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day up 0.1%. By the end of trading, Abbott Laboratories rose 81 cents (2.3%) to $36.12 on average volume. Throughout the day, 10.4 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 11.3 million shares. The stock ranged in a price between $35.34-$36.15 after having opened the day at $35.45 as compared to the previous trading day's close of $35.31. Other companies within the Health Services industry that increased today were: Universal American ( UAM), up 8.3%, CombiMatrix Corporation ( CBMX), up 7.1%, Addus Homecare Corporation ( ADUS), up 6.6%, and DaVita HealthCare Partners ( DVA), up 6.1%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $55.48 billion and is part of the health care sector. The company has a P/E ratio of 9.5, below the S&P 500 P/E ratio of 17.7. Shares are up 7.8% year to date as of the close of trading on Monday. Currently there are eight analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share.